Combo is preferentially active in T-cell lymphomas

Print Friendly, PDF & Email


Lorenzo Falchi, MD
Photo by Larry Young
A 2-drug combination has demonstrated preferential activity in T-cell lymphomas over B-cell lymphomas, according to researchers. In a small, phase 1/2 study, treatment with oral 5-azacitidine and romidepsin produced a higher overall response rate (ORR) and prolonged progression-free survival (PFS) in patients with T-cell lymphomas. “In... [Read Article]
Print Friendly, PDF & Email

Brentuximab vedotin sBLA receives priority review

Print Friendly, PDF & Email


Brentuximab vedotin
Photo from Business Wire
The US Food and Drug Administration (FDA) has accepted for priority review a supplemental biologics license application (sBLA) for brentuximab vedotin (ADCETRIS). With this sBLA, Seattle Genetics, Inc., is seeking approval for brentuximab vedotin in combination with chemotherapy for frontline treatment of patients with advanced classical Hodgkin... [Read Article]
Print Friendly, PDF & Email

Inhibitor exhibits activity against range of lymphomas

Print Friendly, PDF & Email


Micrograph showing DLBCL
Preclinical research suggests the dual PI3K/mTOR inhibitor PQR309 has activity against several types of lymphoma and works well in combination with other agents. PQR309 exhibited anti-lymphoma activity as a single agent and in combination with venetoclax, panobinostat, ibrutinib, lenalidomide, ARV-825, marizomib, and rituximab. PQR309 demonstrated greater activity against B-cell lymphoma... [Read Article]
Print Friendly, PDF & Email

Natural selection opportunities tied to cancer rates

Print Friendly, PDF & Email


Cancer patient receiving chemotherapy
Photo by Rhoda Baer
Countries with the lowest opportunities for natural selection have higher cancer rates than countries with the highest opportunities for natural selection, according to a study published in Evolutionary Applications. Researchers said this is because modern medicine is enabling people to survive cancers, and their genetic... [Read Article]
Print Friendly, PDF & Email